Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
East Mediterr Health J ; 28(9): 673-681, 2022 Sep 29.
Article in English | MEDLINE | ID: covidwho-2067577

ABSTRACT

Background: Incomplete data are often presented for determining the role of vitamin A supplement therapy for improving treatment outcomes in patients with COVID-19. Aims: We compared treatment effects between a group that received vitamin A added to the standard COVID-19 treatment and another group that received the standard drug treatment alone. Methods: Participants in this triple-blind controlled trial comprised 182 COVID-19 outpatients in Saveh City, Markazi Province, Islamic Republic of Iran, in 2020. Patients were randomly divided into experimental (n = 91) and control (n = 91) groups. Patients in the control group received the national standard treatment for COVID-19 (hydroxychloroquine), and those in the intervention group received 25 000 IU/d oral vitamin A for 10 days in addition to the standard treatment recommended by the national protocol. We evaluated the clinical symptoms, paraclinical criteria, and hospitalization status before and after 10 days of interventions. Results: The treatment groups did not differ significantly in clinical and paraclinical symptoms before the intervention. However, clinical symptoms such as fever, body ache, weakness and fatigue, paraclinical symptoms, white blood cell count, and C-reactive protein showed significantly greater decreases in the experimental group 10 days post-intervention compared with the standard treatment alone (P < 0.05). Conclusion: Vitamin A supplementation demonstrated efficacy in improving some clinical and paraclinical symptoms in patients with COVID-19. Future studies should evaluate vitamin A supplementation with a larger sample size and compare different dosages, especially in hospitalized patients.


Subject(s)
COVID-19 , C-Reactive Protein , COVID-19/drug therapy , Dietary Supplements , Humans , Hydroxychloroquine/therapeutic use , SARS-CoV-2 , Treatment Outcome , Vitamin A/therapeutic use
3.
BMC Psychol ; 10(1): 68, 2022 Mar 16.
Article in English | MEDLINE | ID: covidwho-1745420

ABSTRACT

BACKGROUND: There is no valid and reliable tool to measure COVID-19 healthcare stress felt by healthcare students. A scale was developed to assess COVID-19 stress in healthcare students and its psychometrics was examined. METHODS: This is a two phases mixed-method study including a qualitative stage consisting of student interview and literature review to develop content of the tool. In the quantitative stage, the psychometrics of the scale was examined in 2020-2021. RESULTS: The COVID-19 related healthcare student stress scale (CHSSS) featured five factors including fear of catching coronavirus, social constraints, changes in education, non-compliance of health protocols and worrying news and overload information, which totally explained 51.75% of the total variance. CONCLUSION: Validity and reliability of CHSSS with 17 items were supported to measure COVID-19 stress in healthcare students as a self-assessment tool. Researchers can utilize this tool to assess COVID-19 stress in healthcare students and introduce policies and intervention especially designed for healthcare students.


Subject(s)
COVID-19 , COVID-19/diagnosis , Delivery of Health Care , Humans , Interviews as Topic , Psychometrics , Qualitative Research , Reproducibility of Results , Students , Surveys and Questionnaires
4.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-305690

ABSTRACT

Background: New Coronavirus disease (COVID-19) is the main pathogens that primarily target the human respiratory organization, represents a public health emergency and global concern. The present study aimed to investigate the epidemiological, clinical characteristics of coronavirus-infected disease (COVID-19) in Saveh city, of Iran, in 2020.MethodIn this descriptive-analytical research, 1142 patients suspected of having coronavirus, participated. Data collection was performed using interviews, inserting information into the researcher-made questionnaires, and using the information in patients' medical records. Data were analyzed by SPSS 21 using Chi-square, independent sample t tests, Fisher's Exact Test, and regression analysis.Resultsmultivariate logistic regression models revealed that among clinical symptoms and patents characteristics, some variables were significant predictors of death: Intubation (OR = 8.82;95% CI: (5.15-15.63), PO2 rate (OR = 2.48;95% CI: (1.51-4.08), Diabetes (OR = 1.88;95% CI: (1.00-3.54), Shortness of breath (OR = 1.70;95% CI: (1.02-2.82). Almost half of the patients (48.3%) had a history of chronic disease, cardiovascular disease (CVD) (12.8%), diabetes (11.6%), and high blood pressure (9.7%) were the primary chronic disease among patients.ConclusionConsidering the results of the study, designing and implementing targeting and tailoring health education programs for all groups of the community and especially for susceptible people such as elderly and patients with chronic disease, are highly recommended. All in all, risk communication programs regarding COVID-19 might be a priority for responsible agencies.

5.
J Complement Integr Med ; 18(4): 775-781, 2021 Mar 31.
Article in English | MEDLINE | ID: covidwho-1160235

ABSTRACT

OBJECTIVES: Herbal medicines, as a treatment method, have received a great deal of attention. The effects of two herbal medicines namely Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients were examined. METHODS: A clinical trial with 100 suspected COVID-19 outpatients as participants was conducted. The participants were allocated randomly to two groups of 50 members. The intervention group received concurrent Zingiber officinale (Tablet Vomigone 500 mg II tds) and Echinacea (Tablet Rucoldup I tds) for seven days in addition to the standard treatment. The control group only received the standard treatment (Hydroxychloroquine). After seven days, alleviation of clinical symptoms and hospitalization rate were examined. In addition, 14 days after treatment, the hospitalization was assessed again by telephone follow up. RESULTS: The two groups were identical in terms of basic characteristics. Improvement level as to coughing, dyspnea, and muscle pain was higher in the intervention group (p value <0.05). There was no significant difference between the two groups in terms of the other symptoms. In addition, the hospitalization rate in the intervention and control groups were 2 and 6% respectively, which are not significantly different (p value >0.05). CONCLUSIONS: Taking into account the efficiency and trivial side-effects of Zingiber officinale and Echinacea, using them for alleviation and control of the clinical symptoms in COVID-19 outpatients is recommended.


Subject(s)
COVID-19 , Echinacea , Ginger , Hospitalization , Humans , Outpatients , SARS-CoV-2 , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL